Wearable EEG monitoring start-up Epitel raises $12.5M to market seizure detection system

by

Epi­tel rais­es $12.5M for wear­able seizure detec­tion sys­tem (Mobi­Health News):

Epi­tel, mak­er of a wear­able elec­troen­cephalo­gram (EEG) sys­tem for seizure detec­tion, announced Wednes­day it had scored $12.5 mil­lion in Series A funding.

The round was led by Cat­a­lyst Health Ven­tures (CHV) and Genoa Ven­tures, with par­tic­i­pa­tion from Dex­com, OSF Ven­tures, Wave­mak­er 360, Med­Moun­tain Ven­tures and Salt Lake City Angels … The com­pa­ny’s first prod­uct, the REMI sys­tem, con­sists of a wear­able, wire­less EEG sen­sor that’s applied below the hair­line, and soft­ware for providers to review data and mon­i­tor for seizures. The sen­sor can con­tin­u­ous­ly mon­i­tor patients for 48 hours.

The plat­form received FDA 510(k) clear­ance for in-hos­pi­tal use in March 2021, but Epi­tel plans to expand into ambu­la­to­ry and at-home care in the future…

Anoth­er com­pa­ny focused on seizure detec­tion is Zeit, which announced in Novem­ber it had raised $2 mil­lion in seed fund­ing. The com­pa­ny makes a head­band device that aims to alert patients to signs of a stroke or seizure. Zeit said the seed invest­ment would go toward hir­ing new team mem­bers and fund­ing a sub­mis­sion to the FDA.

Remote mon­i­tor­ing com­pa­ny Empat­i­ca makes an FDA-cleared wrist-worn device for peo­ple with epilep­sy to alert users and their care­givers of con­vul­sive seizures.

The Announcement:

Epi­tel Secures $12.5 Mil­lion Series A Financ­ing for Wear­able, Wire­less EEG Mon­i­tor­ing Sys­tem (press release):

Epi­tel, Inc., a dig­i­tal health com­pa­ny devel­op­ing a wear­able, wire­less EEG mon­i­tor­ing plat­form for seizure detec­tion, announced today the clos­ing of a $12.5 mil­lion Series A financ­ing for ini­tial pilot com­mer­cial­iza­tion and fur­ther devel­op­ment of its pro­pri­etary plat­form. Epi­tel received FDA clear­ance for its first prod­uct, a wire­less and wear­able EEG (brain wave mon­i­tor) sen­sor, and remote access soft­ware known as REMI® for use with­in hos­pi­tal emer­gency rooms and crit­i­cal care units. REMI first received clear­ance from the U.S. Food & Drug Admin­is­tra­tion in 2021.

Two-thirds of the U.S. pop­u­la­tion lack ready access to EEGs and most emer­gency depart­ments lack the capa­bil­i­ty to ade­quate­ly mon­i­tor EEG … REMI, Epitel’s first FDA-cleared prod­uct solves this prob­lem with wear­able, wire­less sen­sors that can be rapid­ly and eas­i­ly applied by a nurse or hos­pi­tal tech­ni­cian. EEG data is then imme­di­ate­ly con­nect­ed to a cloud-based soft­ware plat­form avail­able to neu­rol­o­gists to review and mon­i­tor for seizures at any time from any loca­tion. Because the Epi­tel Sys­tem is wear­able and wire­less, it can con­tin­ue to mon­i­tor the patient con­tin­u­ous­ly for 48 hours dur­ing their hos­pi­tal journey.

“It is time that EEGs for the brain become as acces­si­ble as EKGs for the heart to patients through­out the coun­try. For too long essen­tial neu­ro­log­i­cal ser­vices have been inac­ces­si­ble to large parts of our pop­u­la­tion,” said Dr. Chaud­ery, Prin­ci­pal with Genoa Ventures.

News in Context: